Physiomics (GB:PYC) has released an update.
Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Physiomics PLC has secured a new contract with Cancer Research UK to develop a pharmacokinetic-pharmacodynamic model for a novel cancer therapy, aiming to refine starting doses for upcoming human trials. This deal highlights Physiomics’ expertise in using advanced data science for drug development and strengthens its ongoing collaboration with Cancer Research UK.
For further insights into GB:PYC stock, check out TipRanks’ Stock Analysis page.
